Basket Study of Brigatinib in Patients with Advanced Solid Tumors with ROS1 Rearrangement
Latest Information Update: 28 Oct 2022
At a glance
- Drugs Brigatinib (Primary)
- Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms Barossa study
- Sponsors Takeda Pharma
Most Recent Events
- 13 Sep 2022 Primary endpoint has been met (objective response rate) , Results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results (n=28) reporting efficacy and data from cohort 1 of this trial in which TKI-naive ROS1-rearranged NSCLC patients were enrolled presented at the 47th European Society for Medical Oncology Congress
- 14 Sep 2021 Results (n=19) of cohort 2 were presented at the 2021 World Conference on Lung Cancer.